Bicara Therapeutics Presents Ficerafusp Alfa Phase 1b Data in HPV-Negative Head and Neck Cancer

• Bicara Therapeutics reported FORTIFI-HN01 substantially enrolled, targeting a mid-2027 interim analysis that could support potential U.S. approval of ficerafusp alfa.
• The drug targets first-line recurrent or metastatic HPV-negative head and neck cancer.
• Phase 1b testing of 1,500 mg weekly with pembrolizumab showed a 54% confirmed response rate; median overall survival reached 21.3 months.
• Median response duration at that dose reached 21.7 months; median progression-free survival was 9.9 months.
• The combination showed no new safety signals; no treatment-related deaths were reported.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.